ALIVUS - Investment Analysis

Last Updated Time : 02 Aug 25, 12:58 am

Investment Rating: 3.6

📊 Fundamental Analysis Summary

Alivus (ALIVUS) shows signs of being a moderately attractive long-term investment, but the lack of complete data—especially on ROE, ROCE, PEG ratio, and quarterly profit—makes it difficult to fully assess its growth trajectory. Still, a few indicators suggest potential

Metric Value Interpretation

P/E Ratio 35.3 Slightly above industry average — priced for growth

EPS ₹359 Very strong — suggests high profitability

Dividend Yield 2.21% Attractive — adds passive income for long-term holders

FII/DII Change -0.15% / +0.43% Mild institutional interest — neutral sentiment

RSI / MACD 44.6 / -0.20 RSI below 50 and MACD negative — short-term weakness, potential entry opportunity

DMA 50 / 200 ₹1,037 / ₹1,029 Price near moving averages — consolidation zone

52W Price Range ₹827 – ₹1,335 Currently near lower end — favorable for accumulation

⚠️ Missing Data Caveats

ROE / ROCE: Without these, capital efficiency is unclear.

PEG Ratio: Critical for valuation vs. growth — absence limits conviction.

PAT Figures: No quarterly profit data — hard to assess earnings momentum.

Debt-to-Equity: Unknown — financial risk cannot be evaluated.

📉 Ideal Entry Price Zone

Given technical indicators and current price positioning

Entry Zone: ₹950 – ₹990

RSI suggests mild oversold conditions.

Near 200-DMA — good support level for accumulation.

🧭 Exit Strategy & Holding Period

Holding Period

2–3 years, assuming earnings and ROE/ROCE data confirm growth.

Exit Strategy

Reassess if price exceeds ₹1,300 without EPS growth.

Exit if dividend yield drops below 1% and ROE (once available) is below 12%.

Key Metrics to Monitor (once available)

ROE > 15%, ROCE > 16%

PEG ratio < 1.5

PAT growth > 10% YoY

🧠 Final Thoughts

Alivus appears promising but lacks transparency in key metrics. If you're already holding, consider maintaining your position while monitoring upcoming earnings and financial disclosures. For new investors, a cautious entry near ₹950–₹990 could be justified, but only with close tracking of future fundamentals.

Would you like help drafting a watchlist of similar mid-cap dividend-paying stocks with stronger visibility on growth metrics?

Edit in a page